These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33021050)

  • 1. In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.
    Ariey-Bonnet J; Carrasco K; Le Grand M; Hoffer L; Betzi S; Feracci M; Tsvetkov P; Devred F; Collette Y; Morelli X; Ballester P; Pasquier E
    Mol Oncol; 2020 Dec; 14(12):3083-3099. PubMed ID: 33021050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
    Bai RY; Staedtke V; Aprhys CM; Gallia GL; Riggins GJ
    Neuro Oncol; 2011 Sep; 13(9):974-82. PubMed ID: 21764822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPK14 (p38α) inhibition effects against metastatic gastric cancer cells: A potential biomarker and pharmacological target.
    Mesquita FP; Moreira-Nunes CA; da Silva EL; Lima LB; Daniel JP; Zuerker WJ; Brayner M; de Moraes MEA; Montenegro RC
    Toxicol In Vitro; 2020 Aug; 66():104839. PubMed ID: 32243890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.
    Paillas S; Causse A; Marzi L; de Medina P; Poirot M; Denis V; Vezzio-Vie N; Espert L; Arzouk H; Coquelle A; Martineau P; Del Rio M; Pattingre S; Gongora C
    Autophagy; 2012 Jul; 8(7):1098-112. PubMed ID: 22647487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.
    De Witt M; Gamble A; Hanson D; Markowitz D; Powell C; Al Dimassi S; Atlas M; Boockvar J; Ruggieri R; Symons M
    Mol Med; 2017 Apr; 23():50-56. PubMed ID: 28386621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
    Liu Q; Zou R; Zhou R; Gong C; Wang Z; Cai T; Tan C; Fang J
    J Cell Biochem; 2015 Jul; 116(7):1213-21. PubMed ID: 25535908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent p38α/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies.
    El-Gamal MI; Anbar HS; Tarazi H; Oh CH
    Eur J Med Chem; 2019 Dec; 183():111684. PubMed ID: 31520926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase.
    Gill K; Singh AK; Kapoor V; Nigam L; Kumar R; Holla P; Das SN; Yadav S; Subbarao N; Mohanti BK; Dey S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2763-9. PubMed ID: 23238519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers.
    Meco D; Attinà G; Mastrangelo S; Navarra P; Ruggiero A
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future prospects of p38α/MAPK14 kinase and its inhibitors.
    Madkour MM; Anbar HS; El-Gamal MI
    Eur J Med Chem; 2021 Mar; 213():113216. PubMed ID: 33524689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
    Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
    Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2- and NCK-interacting Kinase Inhibitor.
    Tan Z; Chen L; Zhang S
    Sci Rep; 2016 Sep; 6():33534. PubMed ID: 27650168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
    Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
    Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
    Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ataxia-telangiectasia mutated (ATM) participates in the regulation of ionizing radiation-induced cell death via MAPK14 in lung cancer H1299 cells.
    Liang N; Zhong R; Hou X; Zhao G; Ma S; Cheng G; Liu X
    Cell Prolif; 2015 Oct; 48(5):561-72. PubMed ID: 26269117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
    Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.